bivalirudin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hirudin derivatives 385 128270-60-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bivalirudin
  • angiomax
  • angiox
  • hirulog
designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition
  • Molecular weight: 2180.32
  • Formula: C98H138N24O33
  • CLOGP:
  • LIPINSKI: 3
  • HAC: 57
  • HDO: 28
  • TPSA: 901.57
  • ALOGS: -4.67
  • ROTB: 66

Drug dosage:

DoseUnitRoute
0.25 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2000 FDA MEDICINES CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 418.92 56.39 64 1573 1003 50602484
Thrombosis in device 280.37 56.39 52 1585 2689 50600798
Coagulation time abnormal 229.99 56.39 28 1609 59 50603428
Device occlusion 152.48 56.39 36 1601 5987 50597500
Retroperitoneal haemorrhage 129.60 56.39 27 1610 2529 50600958
Heparin-induced thrombocytopenia 123.17 56.39 28 1609 3937 50599550
Cardiac procedure complication 89.08 56.39 13 1624 144 50603343
Thrombosis 83.06 56.39 39 1598 55794 50547693
Coronary artery perforation 80.34 56.39 10 1627 27 50603460
Coronary artery dissection 69.17 56.39 13 1624 714 50602773
Coagulation time prolonged 68.91 56.39 14 1623 1154 50602333
Haemorrhage 66.35 56.39 33 1604 53408 50550079
Cardiac tamponade 65.19 56.39 17 1620 4215 50599272
Coronary artery occlusion 64.20 56.39 19 1618 7484 50596003
Procedural complication 62.99 56.39 17 1620 4806 50598681
Post procedural complication 62.39 56.39 22 1615 15082 50588405
Vascular stent thrombosis 60.21 56.39 12 1625 897 50602590

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombosis in device 506.93 53.49 100 2117 3064 29569246
Coronary artery thrombosis 481.11 53.49 89 2128 1916 29570394
Coagulation time abnormal 351.89 53.49 48 2169 108 29572202
Procedural complication 136.43 53.49 36 2181 4024 29568286
Thrombosis 134.29 53.49 65 2152 42980 29529330
Heparin-induced thrombocytopenia 120.03 53.49 34 2183 4945 29567365
Vascular stent thrombosis 106.39 53.49 27 2190 2583 29569727
Device occlusion 90.16 53.49 28 2189 5580 29566730
Acute myocardial infarction 74.84 53.49 46 2171 48392 29523918
Coronary artery dissection 67.63 53.49 12 2205 199 29572111
Kounis syndrome 65.15 53.49 17 2200 1812 29570498
Oesophageal ulcer haemorrhage 62.48 53.49 11 2206 174 29572136
Haemorrhage intracranial 57.70 53.49 26 2191 14516 29557794
Cardiac procedure complication 57.36 53.49 10 2207 149 29572161
Reperfusion injury 56.20 53.49 9 2208 77 29572233
Chest pain 55.39 53.49 54 2163 111919 29460391

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 651.92 50.14 116 3424 2753 64492439
Thrombosis in device 598.12 50.14 118 3422 4953 64490239
Coagulation time abnormal 432.35 50.14 58 3482 169 64495023
Heparin-induced thrombocytopenia 237.41 50.14 61 3479 8418 64486774
Procedural complication 173.11 50.14 46 3494 7219 64487973
Vascular stent thrombosis 170.16 50.14 39 3501 3325 64491867
Thrombosis 169.91 50.14 81 3459 70561 64424631
Device occlusion 163.42 50.14 47 3493 9866 64485326
Acute myocardial infarction 123.47 50.14 65 3475 69653 64425539
Retroperitoneal haemorrhage 107.31 50.14 29 3511 4839 64490353
Coronary artery perforation 105.48 50.14 15 3525 74 64495118
Coagulation time prolonged 103.81 50.14 24 3516 2122 64493070
Coronary artery dissection 93.99 50.14 19 3521 891 64494301
Cardiac procedure complication 92.84 50.14 16 3524 309 64494883
Cardiac tamponade 92.50 50.14 29 3511 8135 64487057
Ventricular fibrillation 88.12 50.14 37 3503 23823 64471369
Cardiac arrest 82.72 50.14 68 3472 153996 64341196
Haemorrhage 81.63 50.14 52 3488 79299 64415893
Haemorrhage intracranial 81.44 50.14 35 3505 23849 64471343
Coronary artery occlusion 77.39 50.14 29 3511 13862 64481330
Electrocardiogram ST segment elevation 74.84 50.14 24 3516 7235 64487957
Cardiogenic shock 68.22 50.14 34 3506 32393 64462799
Reperfusion injury 65.54 50.14 11 3529 180 64495012
Post procedural complication 65.33 50.14 29 3511 21324 64473868
Pulmonary haemorrhage 64.51 50.14 25 3515 13084 64482108
Coagulation time shortened 64.11 50.14 12 3528 374 64494818
Chest pain 59.83 50.14 69 3471 235911 64259281
Oesophageal ulcer haemorrhage 53.20 50.14 11 3529 577 64494615
Hypotension 51.50 50.14 82 3458 380892 64114300

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AE06 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct thrombin inhibitors
FDA MoA N0000009963 Thrombin Inhibitors
FDA EPC N0000175518 Direct Thrombin Inhibitor
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA EPC N0000175980 Anti-coagulant
CHEBI has role CHEBI:50249 anticoagulants
CHEBI has role CHEBI:65232 thrombin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008
Unstable Angina Pectoris during PTCA indication
Acute coronary syndrome off-label use 394659003
Intracranial hemorrhage contraindication 1386000
Bleeding contraindication 131148009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.51 acidic
pKa3 3.89 acidic
pKa4 4.04 acidic
pKa5 4.21 acidic
pKa6 4.49 acidic
pKa7 9.65 acidic
pKa8 11.93 acidic
pKa9 12.59 acidic
pKa10 12.84 acidic
pKa11 13.06 acidic
pKa12 13.08 acidic
pKa13 13.4 acidic
pKa14 13.64 acidic
pKa15 13.69 acidic
pKa16 13.81 acidic
pKa17 13.99 acidic
pKa18 10.75 Basic
pKa19 8.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prothrombin Enzyme INHIBITOR Ki 8.60 IUPHAR CHEMBL

External reference:

IDSource
4021268 VUID
N0000148708 NUI
D03136 KEGG_DRUG
285044 RXNORM
C0168273 UMLSCUI
CHEBI:59173 CHEBI
CHEMBL2103749 ChEMBL_ID
CHEMBL3989957 ChEMBL_ID
DB00006 DRUGBANK_ID
C074619 MESH_SUPPLEMENTAL_RECORD_UI
6470 IUPHAR_LIGAND_ID
7282 INN_ID
TN9BEX005G UNII
16129704 PUBCHEM_CID
15879 MMSL
234768 MMSL
41019 MMSL
d04744 MMSL
009031 NDDF
129498009 SNOMEDCT_US
400610005 SNOMEDCT_US
4021268 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9572 INJECTION 250 mg INTRAVENOUS NDA 25 sections
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9576 INJECTION 500 mg INTRAVENOUS NDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Angiomax HUMAN PRESCRIPTION DRUG LABEL 1 0781-3447 INJECTION 250 mg INTRAVENOUS NDA 25 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-9158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 16729-275 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 52958-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 23 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 55111-652 INJECTION 250 mg INTRACAVERNOUS ANDA 25 sections
BIVALIRUDIN Human Prescription Drug Label 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 67457-256 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70436-025 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 250 mg INTRAVENOUS ANDA 26 sections
Angiomax RTU HUMAN PRESCRIPTION DRUG LABEL 1 70511-141 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70860-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
Bivalirudin RTU HUMAN PRESCRIPTION DRUG LABEL 1 70860-403 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 26 sections
BIVALIRUDIN HUMAN PRESCRIPTION DRUG LABEL 1 71288-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 72572-035 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections